FDA announcements can make or break a stock. These four events are the most important ones this month.
News & Analysis: Intra-Cellular Therapies
This is your last chance to buy these companies' stocks before the Food and Drug Administration weighs in on the fates of their key candidate treatments.
The remaining weeks of December are chock-full of clinical trial results and FDA approval decisions that savvy investors can take advantage of.
ITCI earnings call for the period ending September 30, 2019.
Down over 18%, the biotech bounces back.
FDA approvals for these drugs could translate to billions of dollars for a few companies.
Bad news in several forms hit some stocks despite a strong session for the overall market.
Bad news on multiple fronts hit stocks.
Investors disliked the biotech's bad news a lot more than they liked its good news.
ITCI earnings call for the period ending March 31, 2019.